Priut Pharmaceuticals' application for a class 4 generic listing of thioponic acid tebutalin was accepted.

Figure 1: Registration of sulphate tebutalin atomized inhalation solution of the four Trump Reit Pharmaceuticals Source: CDE Official Website Figure 2: Top20 of end-chemical inhalant varieties in China's public medical institutions Source: Minet China's public medical institutions terminal competition pattern Mi Intranet data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal chemical inhaler varieties TOP20, 8 of the 1 billion varieties, Tebutalin ranked top 6.
inhaler can be used for bronchial spasms caused by bronchial asthma, chronic bronchitis, obstructive emphysema, or other lung disorders.
Table 1: Currently under review for the listing of Tebutalin inhalants Source: Minet MED2.0 China Drug Review Database Currently approved domestic pharmaceutical companies have Haizheng Pharmaceuticals' sulphuric acid Tebutalin inhalation powder spray, Sichuan Meida Kang Huakang Pharmaceuticals' sulfate tebtalin atomized inhalation solution for 6 types of imitation, the variety has no enterprise evaluation.
Health Yuan, Shijiazhuang four drugs, Hebei Renhe Yikang Pharmaceuticals, Suzhou Hongsen Pharmaceuticals four types of imitation listing applications are currently in the review and approval, pending the approval of domestic inhalers to enter the market, is expected to seize AstraZeneta's market share.
source: CDE official website, Mi Net database Original title: Sichuan pharmaceutical companies to make further efforts, into the market more than 1 billion inhalants! The AZ exclusive market is over.